Meijer debuts new Chicago-area Marketplace store
GRAND RAPIDS, Mich. — Meijer has brought its Marketplace format to the Chicago area.
The new Meijer Marketplace is located in Cermak Plaza of Berwyn, Ill. At more than 91,000 sq. ft., the Berwyn-based Meijer Marketplace features national and Meijer-branded grocery items, along with a full-service pharmacy offering a variety of national and Meijer-branded health and beauty products.
"We are very pleased to continue our growth in Chicagoland," Meijer co-chairman Hank Meijer said. "Our team has worked very hard to get our new Berwyn store ready, and we’re excited to bring the Meijer difference to customers in Berwyn and the surrounding communities."
Meijer opened its first Chicago-area store in Bolingbrook in 1999. With the addition of the Berwyn store, Meijer now has 15 stores in the Chicago area ranging in size from full supercenters to the smaller Marketplace concepts. More than 180 new jobs were created by the opening of the new Berwyn Marketplace store.
Clif recalls certain lots of blueberry crisp bars
EMERYVILLE, Calif. — Clif Bar on Monday initiated a voluntary recall of a small amount of 12-pack blueberry crisp Clif bars and individual mislabeled blueberry crisp Clif Bars in chocolate chip Clif bar wrappers with the "best by" date of 17MAR13G3, which were distributed to a limited number of stores predominately east of the Mississippi River.
The 12-packs may contain blueberry crisp Clif bars that are mislabeled with chocolate chip Clif bar wrappers and do not list almonds in the ingredient statement. Clif is taking this precautionary safety step for people who are allergic to almonds.
A small quantity of blueberry crisp Clif bars were inadvertently placed in chocolate chip Clif bar wrappers and these mislabeled bars were placed inside correctly labeled blueberry crisp Clif bar 12-pack boxes. The chocolate chip Clif bar wrappers contain advisory allergen labeling, which states that the product may contain traces of tree nuts.
No other Clif Bar products, pack sizes, flavors or "best by" date codes are affected, the company said.
Pfizer will shepherd OTC Nexium through switch process
NEW YORK — Pfizer will be the next consumer healthcare company to reach the market with a switched proton-pump inhibitor. Pfizer on Monday afternoon announced that it has entered into an agreement with AstraZeneca for the over-the-counter rights to Nexium.
“Nexium is one of the most recognized and respected products in its class with tremendous brand equity and loyalty,” Pfizer Consumer Healthcare president Paul Sturman said. “By working with AstraZeneca to offer upon regulatory approval an over-the-counter version of Nexium – a brand people know and trust – we are taking another crucial step to empower consumers by providing convenient access to important healthcare products.”
Pfizer will acquire the exclusive global rights to market Nexium for the approved over-the-counter indications in the United States, Europe and the rest of the world. Under the agreement, Pfizer will make an upfront payment of $250 million to AstraZeneca, and AstraZeneca is eligible to receive milestone and royalty payments based on product launches and sales.
Nexium was launched by AstraZeneca in Europe in 2000 and the U.S. in 2001, as its predecessor Prilosec OTC was being presented as a possible switch candidate.
AstraZeneca will continue to manufacture and market the prescription product, as well as supply Pfizer with the OTC product upon the receipt of regulatory approval. A marketing authorization application for OTC Nexium in a 20-mg tablet form was filed with the European Medicines Agency in June 2012. A new drug application filing for OTC Nexium in the U.S. in 20-mg delayed-release capsules is targeted for the first half of 2013. If approved, Pfizer anticipates commercializing this product in the U.S. beginning in 2014 with launches in other markets to follow.
In addition, both companies are exploring the potential for a strategic partnership that could include similar agreements for other AstraZeneca prescription brands for which OTC versions might be appropriate. The companies have signed an agreement giving Pfizer a right of first refusal regarding OTC rights for Rhinocort Aqua, a pump spray containing the glucocorticosteroid budesonide, with a local anti-inflammatory effect, for the treatment of noninfectious rhinitis (such as hay fever and house dust mite allergy).